国際学会業績　HP用　2021年度～2003年度

【2021年度】

1. Hiraide S，Takahashi M，Yoshida Y，Komine K，Ishioka C．The functional roles of miRNA-193a-3p in colorectal cancer．AACR Annual Meeting 2021．Online (Philadelphia)．Poster. April 10-15 and May 17-21 (2021)
2. Kudo R，Kubo T，Mori Y，Harada Y，Shirota H，Hayashi H，Kano M，Shimizu Y，Ishibashi E，Akita H，Matsubara H，Nishihara H，Ishioka C，Sueoka-Aragane N，Muto M，Toyooka S，Tateishi U，Hirakawa A，Miyake S，Ikeda S．A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial).2021 ASCO Annual Meeting．Online．Poster. June 4-8 (2021)
3. Amano T，Sunami K，Naitio Y，Ennishi D，Imai M，Kage H，Kanai M，Kenmotsu H，Komine K，Koyama T，Maeda T，Morita S，Saigusa Y，Sakai D，Kinoshita I，Kozuki T，Sakashita H，Kohsaka S，Tsuchihara K，Yoshino T．Japanese Society of Medical Oncology/Health Authority of the Japanese Government Cooperative Virtual Educational Program for Improving the Clinical Annotation for Cancer Genomic Medicine．ESMO Congress 2021．Online．Poster. Sep 16 (2021)
4. Komine K，Sunami K，Naito Y，Amano T，Ennishi D，Imai M，Kage H，Kanai M，Kenmotsu H，Koyama T，Maeda T，Morita S，Sakai D，Kohsaka S，Tsuchihara K，Saigusa Y，Yamanaka T，Yoshino T．Chronological improvement in precision oncology implementation in Japan．ESMO Congress 2021．Online．Poster. Sep 16 (2021)
5. Kage H，Sunami K，Naito Y，Amano T，Ennishi D，Imai M，Kanai M，Kenmotsu H，Komine K，Koyama T，Maeda T，Morita S，Saigusa Y，Sakai D，Yamanaka T，Kohsaka S，Tsuchihara K，Yoshino T．Concordance analysis of treatment recommendations between central consensus and multidisciplinary tumor boards．ESMO Congress 2021．Online．Mini Oral. Sep 20 (2021)

【2020年度】

1. Umegaki S，Shirota H，Ishioka C．Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic tumor cells induce anti-tumor immunity．AACR Virtual Annual Meeting Ⅱ．Online．E-Poster. Jun 22-24 (2020)

【2019年度】

1. Ishioka C．Overview: Situation in Japan．National Societies Committee Meeting - ESMO Asia 2019．Singapore．Short talk. Nov 24 (2019)
2. Yuki S，Gamoh M，Denda T，Takashima A，Takahashi S，Nakamura M，Ohori H，Yamaguchi T，Kobayashi Y，Baba H，Kotake M，Amagi K，Kondo H，Shimada K，Sato A，Ishioka C，Komine K，Ouchi K，Morita S，Komatu Y．Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer．2020 Gastrointestinal Cancers Symposium．San Francisco, USA．Poster. Jan 23 (2020)
3. Ishioka C．The Advanced Research Center for Innovations in Next-Generation Medicine(INGEM) and personalised medicine．UK-Japan Symposium on Data-Driven Health: Data strategies to predict risk, prevent and manage disease in individuals and populations．London．Symposium. Feb 26 (2020)

【2018年度】

1. Kasahara Y，Shirota H，Ishioka C．Contribution of FcγRIIB to creating suppressive tumor micrienvironment．AACR 2018．Chicago, USA．Poster. April 17 (2018)
2. Sakai D，Kanai M，Kobayashi S，Eguchi H，Baba H，Seo S，Taketomi A，Takayama T，Yamaue H，Ishioka C．(GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)．ESMO2018．Munich．Poster. Oct 21 (2018)
3. Nakamura M，Takashima A，Denda T，Gamoh M，Iwanaga I，Komatsu Y，Takahashi M，Ohori H，Sekikawa T，Tsuda M，Kobayashi Y，Miyamoto Y，Kotake M，Ishioka C，Shimada K，Sato A，Yuki S，Morita S，Takahashi S，Yamaguchi T．Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer．ESMO2018．Munich．Poster. Oct. 21 (2018)
4. Matsuoka A，Tsubata Y，Yanagawa M，Mizutani T，Takahashi M，Shimodaira H，Hamamoto Y，Nagashima F，Ando Y．Development of training course for broadening the field of geriatric oncology in Japan．International Society of Geriatric Oncology 2018 Annual Conference．Amsterdam, Netherlands．Poster. Nov 16 (2018)
5. Saijo K，Imai H，Chikamatsu S，Kasahara Y，Shirota H，Katoh T，Ishioka C．FK-A11, an HDAC/PI3K dual inhibitor, enhances the efficacy of anti-PD-1 antibody in a mouse model of melanoma．AACR JCA 11th joint conference．Maui．Poster. Feb 12 (2019)

【2017年度】

1. Komatsu Y，Takashima A，Denda T，Gamoh M，Iwanaga I，Shimodaira H，Nakamura M，Yamaguchi T，Takahashi H，Kobayashi K，Tsuda M，Kobayashi Y，Baba H，Kotake M，Ishioka C，Sato A，Yuki S，Morita S，Takahashi S，Shimada K．Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer．ESMO2017．Madrid．Oral. Sep.9 (2017)
2. Takahashi S，Fukui T，Nomizu T，Kakugawa Y，Ishida T，Yamaguchi S，Kato S，Ohuchi N，Gondo N，Ishioka C．Development of TP53 signature diagnostic system using multiplex RT-PCR and observational study to confirm the prognostic value of TP53 signature in breast cancer．ESMO2017．Madrid．Poster. Sep.11 (2017)
3. Yamaguchi S，Takahashi S，Nomizu T，Kakugawa Y，Ishida T，Kato S，Ishioka C．Molecular feature and clinical use development of gene expression profile “TP53 signature” in early stage breast cancer．ESMO2017．Madrid．Poster. Sep.11 (2017)
4. Okita A，Takahashi S，Ouchi K，Inoue M，Yamada Y，Ishioka C．The consensus molecular subtypes of colorectal cancer as a predictive factor for chemotherapies against metastatic colorectal cancer．2018 Gastrointestinal Cancers Symposium．San Francisco, USA．Poster. Jan 20 (2018)

【2016年度】

1. Ito S，Shirota H，Ishioka C．IL-4 modulate the tumor microenvironment and response to cancer therapies．AACR 2016．New Orleans, USA．Poster. Apr 18 (2016)
2. Shirota H，Klinman D M，Ito S，Ishioka C．IL-4 derived from T follicular helper cells in tumor draining lymph nodes regulate myeloid cell properties and anti-tumor immunity ．AACR 2016．New Orleans, USA．Poster. Apr 18 (2016)
3. Takahashi H，Takahashi M，Takahashi S，H. S，Ishioka C．microRAN-193a-3p acts as a tumor suppressor in BRAF-mutated colorectal cancer．AACR 2016．New Orleans, USA．Poster. Apr 18 (2016)
4. Nishida T，Takagi M，Ozaka M，Kitagawa Y，Kurokawa Y，Komatsu Y，Ishioka C，Doi T，Cho H，Kanda T，Sugiyama T，Sawaki A，Kakeji Y，Hirai T，Hato S，Baba H，Shirao K，Hirota S，Kagimura T，Masuzawa T．This abstract will not be presented at the 2016 ASCO Annual Meeting but has been published in conjunction with the meeting.2016 ASCO Annual Meeting．Chicago, Illinois, USA．June 3-7 (2016)
5. Tahara M，Kiyota N，Yokota T，Hasegawa Y，Muro K，Takahashi S，Onoe T，Homma A，Taguchi J，Suzuki M，Minato K，Yane K，Ueda S，Hara H，Saijo K，Yamanaka T．Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)．2016 ASCO Annual Meeting．Chicago, Illinois, USA．Poster. June 4 (2016)

【2015年度】

1. Mori T，Sumii M，Fujishima F，Ueno K，Emi M，Nagasaki M，Ishioka C，Chiba N．Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma．AACR Annual Meeting 2015．Philadelphia, USA．Poster. Apr.22 (2015)
2. Kishino M，Kizawa Y，Sato Y，Miyashita M，Morita T，Hamano J，Hosokawa T．Which pain scale is easy to use for cancer patient? -A cross-sectional survey-．11th Asia Pacific Hospice Conference．Taipei, Taiwan．Apr 30 - May 3 (2015)
3. Sato Y，Miyashita M，Fujimori K，Nakaya J，Fijimoto Y，Kurihara M，Sato K，Ishioka C．Quality indicators of end-of-life cancer care in a Japanese university hospital．11th Asia Pacific Hospice Conference．Taipei, Taiwan．Apr 30 - May 3 (2015)
4. Nishida T，Kitagawa Y，Kurokawa Y，Komatsu Y，Ishioka C，Doi T，Yamada Y，Ozaka M，Cho H，Kanda T，Sugiyama T，Sawaki A，Kakeji Y，Hirai T，Hato S，Baba H，Shirao K，Hirota S，Kagimura T．ReGISTry Study of High Risk GIST Patients After Complete Resection:The adjuvant therapy and pathological diagnosis in Japan.2015 ASCO Annual Meeting．Chicago, USA．Poster. May 29 (2015)
5. Ouchi K，Takahashi S，Yamada Y，Tsuji S，Tatsuno K，Takahashi H，Takahashi N，Takahashi M，Shimodaira H，Aburatani H，Ishioka C．DNA methylation profile correlates to the clinical outcomes of anti-EGFR treatment for metastatic colorectal cancer．18th ECCO-40th ESMO．Vienna, Austria．Poster. Sep 25-29 (2015)
6. Saijo K，Narita K，Katoh T，Ishioka C．In vivo antitumor activity of FK-A11, a depsipeptide analog targeting both histone deacetylase and phosphoinositide 3-kinase．ESMO Asia 2015．Singapore．Poster. Dec 19 (2015)
7. Nishida T，Kondo M，Ozaka M，Cho H，Komatsu Y，Doi T，Baba H，Kitagawa Y，Kurokawa Y，Kanda T，Sugiyama T，Sawaki A，Kakeji Y，Hirai T，Hato S，Shirao K，Ishioka C，Hirota S，Kagimura T，Takagi M．Clinicopathological features of ruptured GIST in the ReGISTry study of high risk GIST patients after complete resection in Japan.2016 Gastrointestinal Cancers Symposium．San Francisco, USA．Poster. Jan 21 (2016)

【2014年度】

1. Takahashi S，Fukui T，Gondo N，Ishida T，Ouchi N，Nomizu T，Kakugawa Y，Ishioka C．TP53-mutation status by gene-expression signature (TP53 signature) and prediction of efficacy of neoadjuvant chemotherapy (NAC) and recurrence after surgery in breast cancer.2014 ASCO Annual Meeting．Cicago, USA．poster. May 31 (2014)
2. Shimodaira H，Zhang X，Komine K，Takahashi M，Takahashi S，Ishioka C．CpG island methylator phenotype is associated with the efficacy of chemotherapy in patients with metastatic colorectal cancer．ESMO2014．Madrid．Poster. Sep.29 (2014)

【2013年度】

1. Okada Y，Kato S，Sakamoto Y，Oishi T，Ishioka C．Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines．AACR Annual Meeting 2013．Washington, USA．Poster. April 8 (2013)
2. Takahashi M．進行神経内分泌腫瘍における集学的治療．Neuroendocrine tumour(NET) Round Table Discussionat ASCO 2013．Chicago USA．Panel discussion. June 2 (2013)
3. Kato S，Gamoh M，Shimodaira H，Murakawa Y，Amagai K，Isobe H，Niitani H，Itoh J，Yoshioka T，Ishioka C．Analysis of cumulative neurotoxicity improvement by withdrawal of L-OHP (Subset analysis of T-CORE0901 Japan-Modified CONcePT trial) ．European Cancer Congress 2013．Amsterdam, Nederland．Poster. Sep 29 (2013)
4. Gamoh M，Sugimoto N，Miwa H，Tsuda M，Nishina S，Okuda H，Imamura H，Matsuyama J，Shimokawa T，Sakai D，Kurokawa Y，Komatsu Y，Tsujinaka T，Ishioka C，Furukawa H．Updated analysis of HERBIS-1: A phase ll study of trastuzumab (T-mab) in combination with tri-weekly S-1 plus CDDP in HER2-positive advanced gastric cancer．2014 Gastrointestinal Cancers Symposium．San Francisco．January 27 (2014)

【2012年度】

1. Toiyama Y，Takahashi M，Hur K，Tanaka K，Inoue Y，Nagasaka T，Kusunoki M，Boland C R，Goel A．Serum miR-21 is a promising biomarker for early detection and prognosis of colorectal cancer．The 103th Annual Meeting of American Association of Cancer Research．McCormick Place, Chicago, IL, USA．Poster section. April 1 (2012)
2. Imai H，Kato S，Sakamoto Y，Takahashi S，Kakudo Y.，Shimodaira H.，C. I．High throughput RNAi screening of synthetic lethal genes interacting with the common TP53 mutation R175H. The 103th Annual Meeting of American Association of Cancer Research． Chicago, USA ．mini symposium. Apr 1 (2012)
3. Saijo K，Katoh T，Shimodaira H，Oda A，Takahashi O，Ishioka C．Identification of romidepsin (FK228) and its analogs as HDAC/PI3K dual inhibitors ．The 103 th Annual Meeting of American Association of Cancer Research．Chicago, USA．Poster. Apr 1 (2012)
4. Takahashi M，Cuatrecasas M，Balaguer F，Hur K，Toiyama Y，Castells A，Boland C R，Goel A．Mir-148a Expression Status Predicts Clinical Outcome in Patients With Advanced Colorectal Cancer (CRC)．DDW2012．San Diego, CA, USA．Oral Presentation. May (2012)
5. Garcia M，Choi C，Kim H R，Toiyama Y，Takahashi M，Goel A，Boland C R，Koi M．Moderate Microsatellite Instability is Associated With Recurrent Distant Metastasis in Stage II and III Primary Colorectal Cancers．DDW2012．San Diego, CA, USA．May 19th (2012)
6. Toiyama Y，Hur K，Takahashi M，Tanaka K，Inoue Y，Kusunoki M，Boland C R，Goel A．Serum miR-200c and miR-203 are Novel Prognostic and Metastasis-Predictive Biomarkers in Patients With Colorectal Cancer (CRC)．DDW2012．San Diego, CA, USA．May 20th (2012)
7. Takahashi S，Ohuchi K，Kato S，Shimodaira H，Kakudo Y，Akiyama S，Yoshida K，Shiono M，Okada Y，Sugiyama S，Saito N，Lee J，Oishi T，Takahashi H，Yoshino Y，Ishioka C．Clinical outcome of recombinant human soluble thrombomodulin (rTM) for patients with disseminated intravascular coagulation (DIC) complicating advanced solid cancer: Retrospective analysis.2012 ASCO Annual Meeting ．Chicago, USA．June (2012)
8. Watanabe G，Ishida T，Takahashi S，C Ishioka，M Watanabe，Ohuchi N．The Combination of Immunohistochemistry for Predicting TP53 Mutation Is Useful Prognostic Marker in Breast Cancer. San Antonio Breast Cancer Symposium．Texas, USA．December 6 (2012)
9. Saijo K，Kato T，Lee J，Shimodaira H，Oda A，Takahashi O，Ishioka C．Romidepsin (FK228) and its analogs exhibit potent cytotoxicity through HDAC/PI3K dual inhibition in colorectal cancer cell lines．AACR/JCA Joint Conference．Hawai,　USA．Poster. Feb 24 (2013)

【2011年度】

1. Takahashi M，Koi M，Balaguer F，Boland C R，Goel A．MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin and a poly(ADP-ribose) polymerase inhibitor．AACR Annual Meeting．Orange County Convention Center, Orlando, FL, USA．Poster section. April 5th (2011)
2. Shen Y，Link A，Takahashi M，Balaguer F，Hur K，Boland C R，Goel A．Boswellia Extracts Induce DNA Methylation Changes in Colon Cancer Cells．DDW2011．Chicago. Poster. May 8th (2011)
3. Takahashi M，Shen Y，Link A，Balaguer F，Boland C R，Goel A．Acetyl-11-Keto-Beta-Boswellic Acid Inhibits Cell Growth, Invasion, and Migration in Colon Cancer Cells by Modulating the Expression of MicroRNA Let-7 and the Mir-200 Family．DDW2011．Chicago. May 8th (2011)
4. Balaguer F，Antelo M，Shen Y，Hur K，Giraldez M D，Bujanda L，Takahashi M，Cabanne A M，Barugel M E，Arnold M A，Roca E L，Andreu M，Llor X，Jover R，Castells A，Boland C R，Goel A．Increased Line-1 Hypomethylation is a Unique Feature of Early-Onset Colorectal Cancer (CRC)．DDW2011．Chicago. May 10th (2011)
5. Hur K，Takahashi M，Balaguer F，Nagasaka T，Hemmi H，Koi M，Boland C R，Goel A．MicroRNA-200c/141 Cluster as a Control Switch Between Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Human Colorectal Cancer Metastasis．DDW2011．Chicago. Poster May 10th (2011)
6. Andoh H，Kato S，Gamoh M，Yamaguchi T，Sakayori M，Sasaki Y，Mori T，Ohori H，Yoshioka T，Ishioka C．A randmized pilot study comparing safety and efficaly of irinotecan plus S-1 plus bevacizmab(IRIS+BV)and modified FOLFIRI plus BV (mFOLFFIRO+BV) in patients (pts) with metastatic colorectal cancer(mCRC):The result of efficacy report of T-CORE0702.．2011 ASCO Annual Meeting．Chicago, USA．not be presented at the 2011 ASCO Annual Meeting but has been published in conjunction with the meeting. June (2011)
7. Nagai H，Yasuda H，Kanai M，Nishimura T，Kitano T，Matsumoto S，Mori Y，Ishiguro H，Kakudo Y，Sato H，Yamaguchi T，Tahakashima S，Nakata K，Kobayashi M，Terada T，Sasaki T，Mio T，Mishima M，Yanagihara K，Fukushima M．A double-Blind, randomized, and multicenter study regarding the effects of solution for gemcitabine on frequency and degree of vascular pain in patients with cancer.2011 ASCO Annual Meeting．Chicago, USA．June (2011)
8. Fujii M，Kim Y H，Satoh T，Hosaka H，Kim T，Tsuji A，Inokuchi M，Takagane A，Oh S C，Tanabe K，Okuno T，Chin K，Ura T，Lee J I，Kakudo Y，Yamaguchi K，Iijima S，Takeuchi M，Kim H，Nakajima T．Randomized phase III study of S-1 alone versus S-1 plus docetaxel(DOC) in the treatment for adovanced gastric cancer(AGC):The START trial update.2011 ASCO Annual Meeting．Chicago, USA．Poster Discussion Session, Gastrointestinal(Noncolorectal)Cancer. June 6 (2011)
9. Gamo M，Kato S，Niitani T，Murakawa Y，Sakayori M，Isobe H，Shimodaira H，Akiyama S，Yoshida K，Yoshioka T，Ishioka C．Phase II intermittent (or stop and go)I-OHP adoministration of first-line bevacizumab(BV)plus mFOLFOX6 or CapeOX theraopies in Japanese patients with mCRC:The interim report of t-CORE0901．ASCO Gastrointestinal Cancers Symposium．San Francisco,　USA．General Poster Session C. Jan19-21 (2012)

【2010年度】

1. Ishioka C，Soeda H，Komine K，Kato S，Shimodaira H．Molecular Target Therapies and Molecular Markers of Metastatic Colorectal Cancer．The Joint Symposium of the 5th International Symposium of Institue Network and the international Symposium Commemorating lnauguration of Kanazawa University Cancer Research Institute．Kanazawa･KKR Hotel Kanazawa．Session4 Tumor Biology and Metastasis2. 　June 25 (2010)
2. Tsushima T，Boku N，Honma Y，Takahashi H，Ueda S，Nishina T，Kawai H，Kato S，Suenaga M，Tamura F．Retrospective analysis of first-line chemotherapy in 132 patients with advanced small-bowel adenocarcinoma．2011 Gastrointestinal Cancers Symposium ．San Francisco, USA．General Poster Session B. January 21 (2011)
3. Kato S，Andoh H，Gamoh M，Yamaguchi T，Murakawa Y，Sasaki Y，Takahashi S，Shimodaira H，Yoshioka T，Ishioka C．A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 (IRIS) plus bevacizumab (BV) and modified (m) FOLFIRI plus BV in patients (pts) with metastatic colorectal cancer (mCRC): First report of T-CORE0702．2011 Gastrointestinal Cancers Symposium ．San Francisco,　USA．General Poster Session C. January 22 (2011)
4. Shimodaira H，Soeda H，Gamoh M，Andoh H，Yamaguchi T，Watanabe M，Isobe H，Sudo T，Kato S，Ishioka C．Phase II trial of cetuximab plus irinotecan for FOLFOX and FOLFIRI-refractory patients with EGFR-positive advanced and/or metastatic colorectal cancer: Evaluation of the efficacy and safety based on KRAS mutation status (T- CORE0801)．2011 Gastrointestinal Cancers Symposium ．San Francisco,　USA．General Poster Session C. January 22 (2011)
5. Mori T，Fujiyoshi M，Hisamichi K，Ishioka C．Phase I/II clinical trial using cancer/testis antigen- and/or VEGFR1/2-derived peptide vaccines for various types of cancers. Immunotherapy: Correcting immune escape in cancer．Philadelphia, USA． Mar 10-11 (2011)
6. Takahiro M，Masachika F，Kanehiko H，Chikashi I．Phase I/II clinical trial using cancer/testis antigen- and/or VEGFR1/2-derived peptide vaccines for various types of cancers. Immunotherapy: Correcting immune escape in cancer．Philadelphia,　USA． Mar 10-11 (2011)

【2009年度】

1. Shimodaira H，Takahashi M，Soeda H，Komine K，Ishioka C．Functional assay for MutYH variants using MutY deficient E.coli.．100th AACR Annual Meeting．Denver, USA．Poster．Apr.19 (2009)
2. Yasuda K，Kato S，Sakamoto Y，Watanabe G，Mashiko S，Sato A，Kakudo Y，Ishioka C．Cytoplasmic localized wild-type p53 and S121F super p53 still retains apoptosis inducible abilities．2009 AACR Annual Meeting ．Denver, USA．Poster．April 19 (2009)
3. Shimodaira H，Soeda H，Takahashi M，Ishioka C．Genetic alterations in colorectal cancer associated with the efficacy of anti-EGFR antibody or cancer predisposition. The 14th Korea-Japan Cancer Research Workshop．Kanazawa・ANACrowneplaza Hotel．Workshop．December 19 (2009)

【2008年度】

1. Hutzen B，Cen L，Friedman L，Sobo M，Ball S，Li P-K，Li C，Fuchs J，Bhasin D，Pandit B，Shibata H，Iwabuchi Y，Lin J．New curcumin analogues with enhanced growth suppressive activity in cancer cells．2008 AACR(American Association for Cancer Research) Annual Meeting．San Diego Convention Center ・USA．Poster（Cancer Prevention２）．April 13 (2008)
2. Wei L，Lan L，Hong Z，Yasui A，Satake M，Ishioka C，Chiba N．Rapid accumulation of BRCA1 at DNA double-strand breaks is dependent on Ku80. Ataxia-Telamgiectasia Workshop 2008 ．Ohtsu Japan．April 22-26 (2008)
3. Yoshioka T，Kato S，Gamoh M，Suzuki T，Shibata H，Shimodaira H，Otsuka K，Kakudo Y，Takahashi S，Ishioka C．Phase 1/2study of sequential combination with irinotecan and S-1 in patients with metastatic colorectal cancer. 2008 ASCO Annual Meeting．Chikago Illinois USA．General Poster Session．June 2 (2008)
4. Mashiko S，Moriya T，Ishida T，Sasano H，Nomizu T，Kakugawa Y，Nomiyama R，Fukui T，Ohuchi N，Ishioka C．A new method for classifying breast cancers by gene expression profile of TP53 status in multiplex RT-PCR. Second JCA-AACR Special Joint Conference The Latest Advances in Breast Cancer Research．Awaji Yumebutai International Conference Center The Westin Hotel Awaji Island, Hyogo, Japan．Poster．July 15 (2008)
5. Ishioka C．大腸癌薬物療法の進歩、日本の標準と国際標準の違いと将来．中日胃腸腫瘍総合治療学術シンポジウム．北京・中日友好病院臨床研究所講学庁．招聘講演．November 6 (2008)
6. Kato S．進行食道癌の治療戦略、外来化学療法の管理、東北臨床腫瘍研究会における臨床試験．中日胃腸腫瘍総合治療学術シンポジウム．北京・中日友好病院臨床研究所講学庁．招聘講演．November 6 (2008)
7. Wei L，Lan L，Hong Z，Yasui A，Ishioka C，Chiba N．Ku80-dependent accumulation of Tumor Suppressor BRCA1 at DNA double-strand breaks induced by laser micro-irradiation．The 8th Internatopnal Symposium on Nano-Biomedical Engineering．Suntec City・ Syngapore．symposium．December 6 (2008)
8. Shibata H．Challenge to control cancer with newly synthesized Curcumin analogs．The Joint Symposium of the 4th International Symposium of Institutes Network and Osaka University Global COE (Frontier Biomedical Science Underlying Organelle Network Biology) Symposium．Hotel Hankyu Expo Park ・Osaka．Young　Investigator　Session．January 31 (2009)
9. Wei L，Lan L，Hong Z，Yasui A，Ishioka C，Chiba N．Ku80-dependent Accumulation of Tumor Suppressor BRCA1 at DNA Double-strand Breaks Induced by Laser Micro-irradiation．9th International Symposium of Tohoku University Global COE Programme, Nano-Biomedical Engineering in the East Asian-Pacific Rim Region．Sendai International Center Sendai ．Poster-session．March 27-28 (2009)

【2007年度】

1. Watanabe G，Kato S，Nakata H，Ishida T，Ohuchi N，Ishioka C．αB crystallin is a novel p53-target gene and required for p53-dependent apoposis. The 98th American Association for Cancer Research Annual Meeting．Los Angeles USA．Minisymposium．April 16 (2007)
2. Shibata H，Sato A，Ohori H，Kakudo Y，Iwabuchi Y，Ishioka C．Chemopreventive Effective of New Curcumin Analogs against Colorectal Carcinogenesis．The 66th Annual Meeting of the Japanese Cancer Association ．Yokohama・Pacifico-Yokohama　．Posters．October 3 (2007)
3. Watanabe G，Kato S，Ishida T，Ohuchi N，Ishioka C．αB－crystallin, a novel p53-target gene product ,interacts with p53 and is required for p53-dependent apoptosis．The 66th Annual Meeting of the Japanese Cancer Association ．Yokohama・Pacifico-Yokohama．Poster．October 3 (2007)
4. Shimodaira H，Takahashi M，Ishioka C．Functional evaluation of valiations in hereditary colon cancer predispose genes．The 66th Annual Meeting of the Japanese Cancer Association ．Yokohama・Pacifico-Yokohama．International Sesseions．October 5 (2007)
5. Wei L，Chiba N，Lan L，Satake M，Yasui A，Ishioka C．The amino terminus and the carboxy terminus of BRCA1use distinct mechanism to accumulate at DNA double -standard breaks ．The 66th Annual Meeting of the Japanese Cancer Association

．Yokohama・Pacifico-Yokohama　．poster．October 5 (2007)

1. Chiba N，Wei L，Lan L，Hong Z，Satake M，Yasui A，Ishioka C．Domain-dependent accumulation of BRCA1 at the sites of DNA damage．AACR-NCI-EORTC International conference Molecular targets and Cancer Therapeutics ．San Francisco ・U.S.A．poster．October　23 (2007)
2. Shibata H，Sato A，Yamakoshi H，Ohori H，Kudo C，Kakudo Y，Iwabuchi Y，Ishioka C．Chemoprevention of colorectal carcinogenesis with newly synthesized curcumin analogues．American Association for Cancer Research Centennial Conference on Translational Cancer Medicine Technologies to Treatment．Suntec Singapore．Poster Session．November 5 (2007)

【2006年度】

1. Ohori H，Shibata H，Kakudo Y，Maeda A，Yoshioka T，Iwabuchi Y，Ishioka C．Identification and possibility of new curucumin analogs bearing the dual enhanced potentials for the degradation of oncoproteins and the stabilization of p53．The 97th American Association for Cancer Research Annual Meeting．Washington, DC,　USA．April 3 (2006)
2. Takahashi M，Shimodaira H，Kanamaru R，Ishioka C．Functional analysis of hMLH1 mutations using yeast and in vitro mismatch repair assays．The 97th American Association for Cancer Research Annual Meeting．Washington, DC., USA．poster．April 3 (2006)
3. Shimodaira H，Takahashi M，Ishioka C．Interaction site of the mismatch repair protein PMS2 with the proapoptotic protein p73．The 97th American Association for Cancer Research Annual Meeting．Washington, DC,　USA．poster．April 4 (2006)
4. Ishioka C，Takahashi S，Ishida T，Moriya T，Ohuchi N．Expression signature of p53 status (p53 signature) for the prediction of TP53 mutation and prognosis in breast cancer．42nd American Society of Clinical Oncology Annual Meeting ．Atlanta,　GA．poster．June3 (2006)
5. Takahashi M，Shimodaira H，Ishioka C．Functional characterization of hMLH1 missense mutations using yeast and in vitro assays．11th International Congress of Human Genetics．Brisbane,　Australia．poster session．August 9 (2006)
6. Ishioka C，Ishida T，Moriya T，Shibata H，Sasano N，Ohuchi H，Takahashi S．Evaluation of prognostic significance of TP53 expression signature in breast cancer．The 11th International Congress of Metastasis Research Society Jointed with the 15th Annual Meeting of Japanese Association for Metastasis Research (Plenary Sessions)．Tokushima, Japan．plenary session．September 6 (2006)
7. Ishioka C．Ｐ53 as a biomarker of human cancer: outcomes of comprehensive mutation and expression analyses．The 3rd International Symposium on Novel perspectives in cancer research and translation to the clinic:The 21st century COE program．Gonryo-Kaikan・Sendai．Oral presentation．November10 (2006)
8. Shibata H，Ohori H，Yamakoshi H，Kakudo Y，Ishioka C，Iwabuchi Y．Chemopreventive effect of newly synthesized curcumin analogs on colorectal carcinogenesis ．The Joint Meeting of The 3rd ISC International　Conference　on Camcere Therapeutics and The 11th International Symposium on Cancer Chemotherapy TARGET 10 CURE．Tokyo．poster．December 6 (2006)
9. Chiba N，Yoshioka T，Takahashi S，Shibata H，Kato S，Shimodaira H，Otsuka K，Kakudo Y，Takahashi M，Yasuda K，Sakamoto Y，Ishioka C．Two cases of breast cancer responding to trastuzumab monotherapy．Asia Pacific Medical Education Initiative, 3rd Asia Pacific Workshop, Molecular targeted Therapy of Cancer．Shanghai China．March 10 (2007)
10. Shimodaira H，Takahashi M，Ishioka C．Functional Assay Of MYH Gene Variations．The 2nd Biennial Scientific Meeting of International Society for Gastrointestinal Hereditary Tumours ．Yokohama, Japan．Poster Presentation．March 29 (2007)
11. Takahashi M，Shimodaira H，Ishioka C．Functional Analysis Of 101 hMLH1 Missense Mutations Using Yeast And In Vitro Assays．The 2nd Biennial Scientific Meeting of International Society for Gastrointestinal Hereditary Tumours ．Yokohama, Japan．Poster presentation．March 29 (2007)

【2005年度】

1. Kakudo Y，Shibata H，Otsuka K，Kato S，Ishioka C．Analysis of relationship between p53-dependent transcriptional activity and its ability to induce apoptosis．The96th American Association for Cancer Research Annual Meeting．Anaheim U.S.A.．Poster Session．April 19 (2005)
2. Chiba N，Cruz D L C，Wei L，Parvin J D，Ishioka C．BRCA1 ubiquitination and of phoshory RNA polymerase Ⅱand functional evaluation of BRCA1 missense mutations ．Era of Hope,Department of Defense,Breast Cancer Research Program Meeting．Philadelphia. USA．Poster．June 11 (2005)
3. Horwitz.A.A.，Starita L M，Chiba N，Keogh M-C，Ishioka C，Parvin J D．BRCA1 protein complexes. Composition and Function．Era of Hope, Department of Defense, Breast Cancer Research Program Meeting．Philadelphia, USA．Poster．June 11 (2005)
4. Oliver M，Langerod A，Carrieri P，Bergh J，Klaar S，Eyfjord J，Theillet C，Rodriguez C，Lidereau R，Bieche I，Varley J，Bignon Y，Uhrhammer N，Winqvist R，Jukkola-Vuorinen A，Niederacher D，Kato S，Ishioka C，Hainaut P，Borresen-Dale A-L．Independent prognostic value of somatic TP53 gene mutation in 1794 breast cancer parients．Third International Symposium on the Molecular Biology of Breast Cancer．Molde, Norway．Poster-Session．June22-26 (2005)
5. Yamaura G，Yoshioka T，Fukuda H，Yamaguchi K，Suzuki M，Furumoto S，Iwata R，Ishioka C．O-[18F] fluorometyl-L-tyrosine as a powerful tracer for monitoring tumor response to the chemotherapy, compred with deoxyglucose and thymidine in vivo ．Annual Congress of the European Association of Nuclear Medicine ．Istanbul, Turkey．Poster-Session．October 17 (2005)

【2004年度】

1. Soussi T，Hamroun D，Kato S，Ishioka C，Beroud C．Reassessment of the p53 mutation database in human disease by data mining with a library of p53 missense mutations．Scientific Meeting of Human Genome Variation Society．Berlin, Germany．Apr (2004)
2. Yoshioka T，Sakayori M，Sakata Y，Kato S，Chida N，Shibata H，Kato S，Otsuka K，Ishioka C．Phase I study of docetaxel and cis-diammine-glycolato platinum (Nedaplatin) in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5fluoro uracil and radiation．The 29th European Society of Medical Oncology Congress．Vienna, Austria．Poster．October 29- November 2 (2004)
3. Kato S，Han S Y，Liu W，Otsuka K，Shibata H，Ishioka C．The function-structure and function-mutation relationship of p53 tumor suppressor protein by high-resolution missense mutation analysis．12th International p53 Workshop．Dunedin, New Zealand．Poster．November 6-10 (2004)
4. Kato S，Shiraishi K，Han S Y，Liu W，Otsuka K，Ishioka C．Isolation of temperature-sensitive mutant from a comprehensive p53 missense mutation library．12th International p53 Workshop．Dunedin, New Zealand．Poster．November 6-10 (2004)
5. Soussi T，Hamroun D，Kato S，Claustres M，Ishioka C，Beroud C．Reassessment of the p53 mutation database in human disease by data mining with a library of p53 missense mutations．12th International p53 Workshop．Dunedin, New Zealand．Oral．November 6-10 (2004)

【2003年度】

1. Sakayori M，Kawahara M，Shiraishi K，Nomizu T，Kudo T，Abe R，Ohuchi N，Takenoshita S，Kanamaru R，Ishioka C．Evaluation of stop-codon assay (SC assay) for identifying protein truncating mutations in the BRCA1 and BRCA2 genes in Japanese familial breast cancer．The94th American Association for Cancer Resarch Annual Meeting 2003．Washington DC. U. S. A．Poster．July (2003)
2. Otsuka K，Suzuki T，Shibata H，Kato S，Sakayori M，Shimodaira H，Kanamaru R，Ishioka C．Analysis of the APC mutation spectrum in yeast with a mismatch repar gene defect．The94th American Association for Cancer Research Annual Meeting 2003．Washington. DC. U. S. A.．Poster．July (2003)